Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Gains from Sales and Divestitures: 2020-2022

  • Cullinan Therapeutics' Gains from Sales and Divestitures fell 83.27% to $46,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $46,000, marking a year-over-year decrease of 83.27%. This contributed to the annual value of $46,000 for FY2022, which is 83.27% down from last year.
  • Cullinan Therapeutics' Gains from Sales and Divestitures amounted to $46,000 in Q4 2022, which was down 83.27% from $275,000 recorded in Q4 2021.
  • In the past 5 years, Cullinan Therapeutics' Gains from Sales and Divestitures registered a high of $275,000 during Q4 2021, and its lowest value of $46,000 during Q4 2022.
  • Over the past 3 years, Cullinan Therapeutics' median Gains from Sales and Divestitures value was $128,358 (recorded in 2020), while the average stood at $149,786.
  • Per our database at Business Quant, Cullinan Therapeutics' Gains from Sales and Divestitures skyrocketed by 114.24% in 2021 and then crashed by 83.27% in 2022.
  • Quarterly analysis of 3 years shows Cullinan Therapeutics' Gains from Sales and Divestitures stood at $128,358 in 2020, then surged by 114.24% to $275,000 in 2021, then plummeted by 83.27% to $46,000 in 2022.
  • Its Gains from Sales and Divestitures stands at $46,000 for Q4 2022, versus $275,000 for Q4 2021 and $128,358 for Q4 2020.